We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01089283
First Posted: March 18, 2010
Last Update Posted: March 18, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Tel-Aviv Sourasky Medical Center
  Purpose

Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors. There are gene mutations that increase the risk for the disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if there is a difference between the metabolic brain function of Parkinson patients that carry one of the two mutations to Parkinson patients with no known mutation.

Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes, Parkinson patients with no known mutation and healthy volunteers as a control group.

The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv Sourasky Medical Center Nuclear Medicine Institute.

The examination results will be given to the participants by a doctor from the neurology department.


Condition
Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic

Resource links provided by NLM:


Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment: 80
Study Start Date: March 2010
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
LRRK2 mutation
Parkinson patients that carry mutation on LRRK2 gene
GBA mutation
Parkinson patients that carry mutation on GBA gene
no mutation
Parkinson patients that don't carry mutation on LRRK2 or GBA genes
healthy
Healthy volunteers

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Diagnosed parkinson patients ages: 40-80
Criteria

Inclusion Criteria:

  • diagnosed Parkinson patients with known genetic characteristics

Exclusion Criteria:

  • patients unable to understand and sign an informed consent
  • minors
  • patients in medical condition that does not allow them to stay still during the examination
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01089283


Contacts
Contact: Einat Even-sapir, PhD, MD 972-3-6974444 ext 3536 evensap@tasmc.health.gov.il
Contact: Ayelet Kurzband, BA 972-3-6974444 ext 3536 ayeletk@tasmc.health.gov.il

Locations
Israel
Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel
Contact: Einat Even-Sapir, MD, PhD    972-3-6974444 ext 3536    Evensap@tasmc.health.gov.il   
Contact: Ayelet Kurzband, BA    972-3-6974444 ext 3536    ayeletk@tasmc.health.gov.il   
Sub-Investigator: Hedva Lerman, MD         
Sub-Investigator: Nir Giladi, PhD, MD         
Sub-Investigator: Anat Milerman         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: Einat Even-Sapir, MD, PhD Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  More Information

Publications:

Responsible Party: Einat Even-Sapir MD, PhD. Head, Dept of Nuclear Medicine, Tel Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT01089283     History of Changes
Other Study ID Numbers: TASMC-10-EES-087-CTIL
First Submitted: March 17, 2010
First Posted: March 18, 2010
Last Update Posted: March 18, 2010
Last Verified: March 2010

Keywords provided by Tel-Aviv Sourasky Medical Center:
parkinson
fdg pet-ct
i123 dat scan
LRRK2
GBA
parkinson patients with known genetic characteristic

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases